is glp 1 r retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide for Weight Loss: TRIUMPH-1

The timing is the strongest clue

How quickly is it shipped

In the Phase 2 obesity trial, the most common adverse events were gastrointestinal, dose-related and mostly mild to moderate

The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and Gastric inhibitory peptide (or glucose-dependent insulinotropic polypeptide or GIP)

Regulators will evaluate TRANSCEND-T2D trial data and assess advantages and risks

If appetite is controlled, weight loss is progressing and side effects at the current dose are acceptable, staying at a dose that is working is a completely reasonable clinical decision